ClinicalTrials.gg
Not yet recruitingNCT07549230Updated Apr 29, 2026

Model-Informed Precision Dosing of Tacrolimus in Pediatric Kidney Transplantation

An observational study in Pediatric Kidney Transplantation, sponsored by Helwan University. Not yet recruiting. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Helwan University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
130
Ages
Up to 18 Years
Sex
All
01

Study summary

The purpose of this study is to develop a novel and applicable dosing algorithm that helps support the clinical decision to achieve tacrolimus levels within the optimal immunosuppression range despite sparse sampling in routine clinical practice in pediatric kidney transplantation. This clinical decision support tool (CDST) is based on a hybrid population pharmacokinetics-machine learning approach aiming for tacrolimus dose individualization and reducing the risk of acute graft rejection.

02

Conditions studied

  • Pediatric Kidney Transplantation
03

In context

Lead sponsor

Helwan University is the lead sponsor of 70 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Pediatric kidney recipients receiving tacrolimus

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric patients (\< 18 years old).
  • First-time kidney transplant recipients who have less than 20% PRA and no DSA.
  • Adherent to tacrolimus for a year post-transplantation.
  • All data, including therapeutic drug monitoring (TDM) data, are available.

Exclusion criteria

Exclusion Criteria:

  • Non-adherent patients to tacrolimus.
  • Unavailable or missing data.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
130 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Development of a novel and applicable dosing algorithm.

    A dosing algorithm that rapidly achieves accurate tacrolimus levels within the optimal immunosuppression range despite sparse sampling in routine clinical practice.

    Time frame: June 2026 - January 2027

Secondary outcomes

  1. Reduction in the risk of acute graft rejection.

    Reduction in the risk of acute graft rejection by developing a clinical decision support tool (CDST) to guide the dose individualization of tacrolimus following pediatric kidney transplantation.

    Time frame: June 2026 - January 2027

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jan 2027, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
Apr 24, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07549230
Lead sponsor
Helwan University
Collaborators
Cairo University
Responsible party
Sondos Mohamed Salem (Teaching Assistant, Helwan University) — Principal investigator
First posted
Apr 24, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Apr 29, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion